Xenetic Biosciences, Inc. (XBIO) stock
XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3067% below fair value
$1.61+0.12 (+8.05%)
Close on Nov 17, 2026Market cap $3.77MP/E –Yield –
Xenetic Biosciences enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Xenetic Biosciences's enterprise value was -$2.10M on Nov 11, 2026, against -$65.77K a year earlier. Over the last 5 years it ranged from -$10.85M to $3.35M, with a median of -$2.10M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$2.10M | – |
| 2025 | Dec 31, 2025 | -$775.16K | – |
| 2024 | Dec 31, 2024 | -$686.43K | – |
| 2023 | Dec 29, 2023 | -$4.49M | – |
| 2022 | Dec 30, 2022 | -$10.85M | – |
| 2021 | Dec 31, 2021 | -$2.43M | -142.1% |
| 2020 | Dec 31, 2020 | $5.79M | – |
| 2019 | Dec 31, 2019 | -$3.93M | -128.6% |
| 2018 | Dec 31, 2018 | $13.74M | -13.9% |
| 2017 | Dec 29, 2017 | $15.96M | -54.9% |
| 2016 | Dec 30, 2016 | $35.43M | – |
See a number that looks wrong?